<DOC>
	<DOCNO>NCT01679405</DOCNO>
	<brief_summary>An open-label , uncontrolled , multicenter phase I/Ib trial investigate safety efficacy BIBW 2992 add standard therapy Gemcitabine/Cisplatin chemo-naïve patient advance and/or metastatic adenocarcinoma biliary tract</brief_summary>
	<brief_title>BIBW 2992 add-on Gem/Cis Advanced Biliary Tract Cancer</brief_title>
	<detailed_description>The primary objective safety toxicity , include maximum tolerated dose , BIBW 2992 give add-on therapy Gem/Cis .</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Male female patient age ≥ 18 year Signed dated write informed consent , Histologically confirm adenocarcinoma gallbladder intrahepatic bile duct extrahepatic bile duct ( metastasize ) histologically prove hepatic metastasis earlier resect histologically proven biliary tract cancer Klatskin tumour ( hilar cholangiocarcinoma ) pain biliary obstruction control adequate biliary drainage , uncontrolled infection ECOG Performance Status 01 LFTs : bilirubin ( total ) ≤ 1.5 x ULN , ALT/ AST/ alkaline phosphatase ≤ 3 2.5 x ULN ( ≤ 5 x ULN liver metastasis present ) No prior systemic treatment ) previous adjuvant chemotherapy allow ( complete ≥ 6 month contain Gemcitabine platinum salt ) ; ii ) previous irradiation ( external radiotherapy , brachytherapy , chemoembolization ) PDT allow , provide still least one unidimensionally measurable target lesion untreated area Resolution side effect prior surgical procedure CTCAE grade ≤ 1 ( except laboratory value specify ) At least 4 week major surgery ( first dose study drug ) Life expectancy least 12 week . Cardiac leave ventricular function rest ejection fraction ( LVEF ) ≥ 50 % Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior start therapy : Haemoglobin &gt; 10.0 g/dl ( =6.2 mmol/l ) , blood transfusion allow Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 ( =1.5x 109/L ) Platelet count ≥ 100,000/μl ( =100x 109/L ) Total bilirubin ≤ 1.5 time upper limit normal ALT AST ≤ 2.5 x institutional upper limit normal ( case liver metastasis : ALT AST ≤ 5 x institutional upper limit normal ) Prothrombin rate &gt; 60 % INR &lt; 1.5 Main exclusion criterion Large surgery ( except diagnostic biopsy ) small surgical procedure , external radiotherapy , brachytherapy , PDT within 30 day prior start treatment . Other tumor type adenocarcinoma ( e.g . leiomyosarcoma , lymphoma ) second cancer except patient squamous basal cell carcinoma skin carcinoma situ cervix effectively treat . History acute cardiac disease : congestive heart failure &gt; NYHA class 2 ; active CAD ( MI 6 month prior study entry allow ) ; Patients immunosuppressant therapy know HIV infection Active clinically serious infection ( &gt; grade 2 NCICTC version 3.0 ) History organ allograft Pregnant breastfeeding patient . Substance abuse , medical , psychological social condition may interfere patient 's participation Any condition unstable could jeopardize safety patient compliance study Gastrointestinal ( GI ) tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease History preexist interstitial lung disease ( ILD ) Patients untreated symptomatic brain metastasis . Persistent Grade 2 great neurotoxicity / neuropathy cause</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>metastatic biliary tract cancer</keyword>
</DOC>